ASH 2015: TOURMALINE: Professor Philippe Moreau (University Hospital, Nantes, France) discusses the Tourmaline study – ixazomib, lenalidomide, dexamethasone (iRd) in R/R myeloma, with opinions on the data from Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK), Professor Gordon Cook (Leeds Teaching Hospitals, UK), Erik Low (Chief Executive Myeloma UK) and Dr Shaji Kumar (Mayo Clinic, Rochester, USA)
Ixazomib improves progression-free survival across subgroups by Thomas R. Collins: The oral proteasome inhibitor (PI) ixazomib with lenalidomide and dexamethasone (IRd) performed well versus placebo plus lenalidomide and… read more.